Literature DB >> 25344227

Mechanisms of hypoxia-mediated immune escape in cancer.

Ivraym B Barsoum1, Madhuri Koti2, D Robert Siemens3, Charles H Graham4.   

Abstract

An important aspect of malignant progression is the acquired ability of tumor cells to avoid recognition and destruction by the immune system (immune escape). Clinical cancer progression is also associated with the development of tumor hypoxia, which is mechanistically linked to the acquisition of malignant phenotypes in cancer cells. Despite the well-established role of hypoxia in tumor cell invasion and metastasis, and resistance to therapy, relatively few studies have examined the contribution of hypoxia to cancer immune escape. Accumulating evidence reveals that hypoxia can impair anticancer immunity by altering the function of innate and adaptive immune cells and/or by increasing the intrinsic resistance of tumor cells to the cytolytic activity of immune effectors. Here, we discuss certain aspects of the contribution of hypoxia to tumor immune escape and provide evidence for a novel role of cyclic guanosine monophosphate (cGMP) signaling in the regulation of hypoxia-induced immune escape. Thus, we propose that activation of cGMP signaling in cancer cells may have important immunotherapeutic applications. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344227     DOI: 10.1158/0008-5472.CAN-14-2598

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

Review 1.  Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.

Authors:  Quoc-Viet Le; Juhan Suh; Yu-Kyoung Oh
Journal:  AAPS J       Date:  2019-05-17       Impact factor: 4.009

Review 2.  Focused Ultrasound for Immunomodulation of the Tumor Microenvironment.

Authors:  Jordan B Joiner; Yuliya Pylayeva-Gupta; Paul A Dayton
Journal:  J Immunol       Date:  2020-11-01       Impact factor: 5.422

3.  Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.

Authors:  Shuang Li; Qingzhu Wei; Qin Li; Bin Zhang; Qiang Xiao
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Rhein enhances the cytotoxicity of effector lymphocytes in colon cancer under hypoxic conditions.

Authors:  Xiangfei Yuan; Wencong Tian; Yang Hua; Lijuan Hu; Jing Yang; Junmuzi Xie; Jiacai Hu; Feng Wang
Journal:  Exp Ther Med       Date:  2018-10-12       Impact factor: 2.447

Review 5.  Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation.

Authors:  Shabnam Shalapour; Michael Karin
Journal:  Immunity       Date:  2019-07-16       Impact factor: 31.745

Review 6.  From mice to humans: developments in cancer immunoediting.

Authors:  Michele W L Teng; Jerome Galon; Wolf-Herman Fridman; Mark J Smyth
Journal:  J Clin Invest       Date:  2015-08-04       Impact factor: 14.808

7.  Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms.

Authors:  Holly M Wobma; Mariko Kanai; Stephen P Ma; Ying Shih; Hao Wei Li; Raimon Duran-Struuck; Robert Winchester; Shahar Goeta; Lewis M Brown; Gordana Vunjak-Novakovic
Journal:  J Immunol Regen Med       Date:  2018-04-25

8.  Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea.

Authors:  Mao-Hong Huang; Xiao-Bin Zhang; Hui-Ling Wang; Liu-Xia Li; Yi-Ming Zeng; Miao Wang; Hui-Qing Zeng
Journal:  Ann Transl Med       Date:  2019-03

Review 9.  The Solid Mechanics of Cancer and Strategies for Improved Therapy.

Authors:  Triantafyllos Stylianopoulos
Journal:  J Biomech Eng       Date:  2017-02-01       Impact factor: 2.097

Review 10.  The impact of hypoxia on tumor-associated macrophages.

Authors:  Anne-Theres Henze; Massimiliano Mazzone
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.